A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis

References

• United Nations Office of Drugs on Crime (UNODC). 2007 World Drug Report. Vienna, Austria: UNODC; 2007.
   Google Scholar
• Hando J, Hall W. HIV risk-taking behaviour among amphetamine users in Sydney, Australia. Addiction 1994;89(1): 79–85.
   PubMedGoogle Scholar
• Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 2002;23(2):145–50.
   PubMedGoogle Scholar
• Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004;29(7):1439–64.
   PubMedGoogle Scholar
• Childress AR, O’Brien CP. Dopamine receptor partial agonists could address the duality of cocaine craving. Trends Pharmacol Sci 2000;21(1):6–9.
   PubMedGoogle Scholar
• Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158(3):377–82.
   PubMedGoogle Scholar
• Weiss F, Markou A, Lorang MT, Koob GF. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self- administration. Brain Res 1992;593(2):314–8.
   PubMedGoogle Scholar
• Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR. Aripiprazole attenuates the discriminative- stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology 2005;30(11):2103–14.
   PubMedGoogle Scholar
• Leite JV, Guimaraes FS, Moreira FA. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 2008;578(2–3):222–7.
   PubMedGoogle Scholar
• Schwabe K, Koch M. Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats. Psychopharmacology (Berlin) 2007;191(3): 759–65.
   PubMedGoogle Scholar
• Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000:20(1):94–8.
   PubMedGoogle Scholar
• Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005;25(4):363–6.
   PubMedGoogle Scholar
• Stoops WW. Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine. Exp Clin Psychopharmacol 2006;14(4): 413–21.
   PubMedGoogle Scholar
• Stoops WW, Lile JA, Glaser PE, Rush CR. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend (ELSEVIER) 2006;84(2):206–9.
   PubMedGoogle Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(20):22–33; quiz 34–57.
   PubMedGoogle Scholar
• Somoza EBS, Himmler C, et alThe Brief Substance Craving Scale—measuring craving in clinical trials. NIDA Res Monogr 1999;180304.
   PubMedGoogle Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261–76.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ No ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p. 218–222.
   Google Scholar
• Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003;416:16–23.
   PubMedGoogle Scholar
• Huber CG, Lambert M, Naber D, Schacht A, Hundemer HP, Wagner TT, Schimmelmann BG. Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophr Res 2008;100(1–3): 342–8.
   PubMedGoogle Scholar
• Rush JA. Abnormal Involuntary Movement Scale (AIMS). In: Handbook of psychiatric measures. American Psychiatric Association; 2000. p. 166–168.
   Google Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672–6.
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11–19.
   PubMedGoogle Scholar
• McCullagh P. Regression models for ordinal data (with discussion). J R Stat Soc Ser B 1980;42:109–42.
   Google Scholar
• Little RJA, Rubin DB. Statistical analysis with missing data. 2nd edn. Hoboken, NJ: John Wiley & Sons Inc.; 2002.
   Google Scholar
• Dackis CA, O’Brien CP. Cocaine dependence: a disease of the brain’s reward centers. J Subst Abuse Treat 2001; 21(3):111–7.
   PubMed Web of Science ®Google Scholar
• Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002;26(4):479–88.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Kuoppasalmi K, Fohr J, Tuomola P, Kuikanmaki O, Vorma H, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007;164(1):160–2.
   PubMedGoogle Scholar
• Newton TF, Reid MS, De La Garza R, Mahoney JJ, Abad A, Condos R, et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine- dependent volunteers. Int J Neuropsychopharmacol 2008; 11(8):1037–45.
   PubMed Web of Science ®Google Scholar
• Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract 2003;57(1):49–54.
   PubMedGoogle Scholar
• Pulvirenti L, Koob GF. Being partial to psychostimulant addiction therapy. Trends Pharmacol Sci 2002;23(4):151–3.
   PubMedGoogle Scholar
• Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;2: CD000967.
   Google Scholar
• Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003;2: CD000440.
   Google Scholar
• Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo- controlled trials. Schizophr Res 2003;61(2–3):123–36.
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65(18):47–56.
   PubMedGoogle Scholar
• Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, Mcquade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berlin) 2006;189(2):259–66.
   PubMed Web of Science ®Google Scholar
• Fischman MW, Schuster CR. Cocaine self-administration in humans. Fed Proc 1982;41(2):241–6.
   PubMedGoogle Scholar
• Griffiths RR, Troisi JR, Silverman K, Mumford GK. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 1993;4(1):3–13.
   PubMedGoogle Scholar